Prevalence and Impact of Social Frailty in Patients with Chronic Obstructive Pulmonary Disease.

"Disclosure KH reports personal fees from AstraZeneca, Boehringer Ingelheim, Kracie Pharma, Ltd., and GlaxoSmithKline outside of the submitted work. AT reports personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, KYORIN Pharmaceutical, and Sanofi outside of the submitted work. NO reports personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, KYORIN Pharmaceutical, Novartis, and Sanofi outside of the submitted work. TH reports personal fees from AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline outside of the submitted work. SS reports personal fees from AstraZeneca, GlaxoSmithKline, KYORIN Pharmaceutical, Sanofi, and Tanabe-Mitsubishi outside of the submitted work. HS reports personal fees from AstraZeneca, Boehringer Ingelheim, Kyorin Pharmaceutical, GlaxoSmithKline, Novartis, Kracie Pharma, Ltd., Gilead Sciences, Tsumura and Co, MSD K.K., and Sanofi outside of the submitted work. The authors report no other conflicts of interest in this work."

"This work was supported by a Grant-in-Aid for Scientific Research (KAKENHI 21K15668)."